logo

• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

메세지 내용

Bacterial bacterial infections. Conclusions: This review demonstrates bacterial and viral co-infection was typical. Additional study with larger sample dimensions is necessary to higher characterize respiratory viral infection in the placing of CAP in the ICU.References 1. IDSA/ATS Suggestions. CID. 44: 27-70, 2007. Lenvatinib two. Johnstone, et al. Upper body. 134 (six): 1141-1148, 2008.P090 The SAATELLITE Examine: Prevention of S aureus Nosocomial Pneumonia (NP) with MEDI4893, a Human Monoclonal Antibody (mAb) From S aureus B. Fran is1, P. F. Laterre2, P. Eggimann3, A. Torres4, M. S chez5, P. F. Dequin6, G. L. Bassi4, J. Chastre7, H. S. Jafri8 one CHU Dupuytren, Limoges, France; 2St Luc College Medical center, Brussels, Belgium; 3CHUV, Lausanne, Switzerland; 4Hospital Clinic of Barcelona, Barcelona, Spain; 5Hospital Cl ico San Carlos, Madrid, Spain; 6Universit?Fran is Rabelais and CHU Bretonneau, Excursions, France; 7Groupe Hospitalier Piti?Salp ri e, Paris, France; 8MedImmune, Gaithersburg, Usa Critical Treatment 2016, twenty(Suppl 2):P090 Introduction: Staphylococcus aureus pneumonia, particularly inside the hospitalized or intensive treatment unit (ICU) populace, is actually a clinically major and really serious condition that contributes appreciably to morbidity and mortality. MEDI4893 is usually a novel mAb that targets, binds, and functionally inhibits S aureus alpha toxin, a significant determinant PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/12711626 of S aureus virulence. The usage of MEDI4893 to circumvent S aureus pneumonia provides a novel paradigm for running certain high-risk sufferers. We describe the rationale and design and style on the SATTELLITE study to research the usage of MEDI4893 in mechanically-ventilated (MV) subjects. This review (EudraCT 2014-001097-34) is becoming performed by means of the Revolutionary Medications Initiative Joint Undertaking from the EU and is a joint collaboration in between Medimmune as well as the academic partners in the Combatting Bacterial Resistance in Europe (COMBACTE), and that is a consortium of gurus from the discipline of antibiotic-resistant microorganisms and ventilator-associated pneumonia. Solutions: SAATELLITE is actually a randomized, double-blind, placebocontrolled, dose-ranging Period two examine to research the efficacy and protection of MEDI4893 in MV topics. The primary efficacy end-P089 Incidence of local community acquired pneumonia with viral an infection in mechanically ventilated clients while in the professional medical intense treatment unit J. O'Neal, H. Rhodes, J. Jancik Hennepin County Medical Middle, Minneapolis, United states of america Important PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/8627573 Treatment 2016, twenty(Suppl 2):P089 Introduction: Group acquired pneumonia (CAP) tips admit respiratory viruses as being a lead to for CAP, but supply fewCritical Care 2016, Volume twenty SupplPage forty four ofpoint may be the incidence of NP brought about by S aureus as a result of thirty times postdose, proposed as being a clinically meaningful, objective and reproduceable endpoint. Safety will probably be assessed by means of 360 times postdose. Subjects will probably be randomized within a one:one:one ratio to get a one intravenous infusion of Low-dose MEDI4893 or High-dose MEDI4893 or placebo and may be followed by means of 359 days write-up dose. Subjects enrolled are ICU individuals aged [>=] 18 yrs intubated and on mechanical ventilator, whose decreased respiratory tract samples are good for S aureus, but have not been identified with new onset of pneumonia before randomization. Final results: N/A Conclusions: The SAATELLITE study represents an impressive preemptive remedy method of avert S aureus nosocomial pneumonia in MV people, by making use of the novel monoclonal antibody MEDI4893, thus offering a whole new paradigm in S aureus in.